It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
TP53 is a classic tumor suppressor, but its role in kidney cancer remains unclear. In our study, we tried to explain the role of p53 in kidney cancer through the p53-related enhancer RNA pathway. Functional experiments were used to explore whether P53-bound enhancer regions 2 (p53BER2) has a role in the cell cycle and senescence response of TP53-wild type (WT) renal cancer cells in vitro or vivo. RNA-sequencing was used to identify the potential target of p53BER2. The results showed that the expression level of P53BER2 was downregulated in renal cancer tissues and cell lines, further dual-luciferase experiments and APR-256-reactivated experiments showed p53BER2 expresses in a p53-dependent way. Moreover, knockdown p53BER2 could reverse nutlin-3-induced cytotoxic effect in TP53-WT cell lines. Further exploration showed the downregulation of p53BER2 could reverse nutlin-3-induced G1-arrest and senescence in TP53-WT cell lines. What is more, the knockdown of p53BER2 showed resistance to nutlin-3 treatment in vivo. Additionally, we found BRCA2 could be regulated by p53BER2 in vitro and vivo; further experiment showed p53BER2 could induce cell-cycle arrest and DNA repair by mediating BRCA2. In summary, the p53-associated enhancer RNA-p53BER2 mediates the cell cycle and senescence of p53 in TP53-WT renal cancer cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Peking University First Hospital, Department of Urology, Beijing, People’s Republic of China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621); Peking University, Institute of Urology, Beijing, People’s Republic of China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319); National Urological Cancer Center, Beijing, People’s Republic of China (GRID:grid.11135.37); Peking University First Hospital, Hereditary Kidney Cancer Research Center, Beijing, People’s Republic of China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621)
2 Peking University First Hospital, Department of Urology, Beijing, People’s Republic of China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621); Peking University, Institute of Urology, Beijing, People’s Republic of China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319); National Urological Cancer Center, Beijing, People’s Republic of China (GRID:grid.11135.37)